GlassScriptPhysician profile
Ripa K Patel
NPI 1811372980
$8,504.28
in general payments reported to CMS, 2019-2025
28 companies · $530 in 2025
The $530 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $554 · 2021: $3,306 · 2022: $573 · 2023: $716 · 2024: $1,331 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,577.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asahi Intecc USA, INC. | $2,522.02 | 2020-2021 | |
| Abiomed | $1,543.38 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $625.65 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $536.36 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $502.16 | 2019-2020 | |
| Medtronic, INC. | $357.81 | 2021-2024 | Launcher |
| Novartis Pharmaceuticals Corporation | $318.98 | 2019-2025 | |
| Amgen INC. | $211.43 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $201.91 | 2019-2024 | |
| Biosense Webster, INC. | $188.68 | 2019 | |
| Abbott Laboratories | $182.03 | 2022-2025 | Jot Dx |
| W. L. Gore & Associates, INC. | $174.95 | 2019-2023 | Gore Cardioform Septal Occluder |
| Merck Sharp & Dohme LLC | $147.63 | 2023-2024 | Verquvo |
| Inari Medical, INC. | $121.85 | 2021 | |
| Angiodynamics, INC. | $120.93 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $118.00 | 2021 | |
| Chiesi USA, INC. | $102.31 | 2023 | Kengreal |
| Regeneron Healthcare Solutions, INC. | $100.57 | 2019-2024 | Evkeeza, Praluent |
| Cardiva Medical, INC. | $98.33 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $85.73 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.51 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $33.04 | 2023-2024 | Brilinta, Farxiga |
| Novo Nordisk INC | $31.84 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Heartflow, INC. | $31.42 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.05 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.61 | 2023 | |
| Terumo Medical Corporation | $15.11 | 2019 | |
| Shockwave Medical, INC | $14.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ripa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.